HER2-positive Metastatic Breast Cancer Clinical Trials

8 recruiting

HER2-positive Metastatic Breast Cancer Trials at a Glance

8 actively recruiting trials for her2-positive metastatic breast cancer are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Houston, New Lenox, and Chicago. Lead sponsors running her2-positive metastatic breast cancer studies include Gustave Roussy, Cancer Campus, Grand Paris, Jules Bordet Institute, and Abramson Cancer Center at Penn Medicine.

Browse her2-positive metastatic breast cancer trials by phase

Treatments under study

About HER2-positive Metastatic Breast Cancer Clinical Trials

Looking for clinical trials for HER2-positive Metastatic Breast Cancer? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-positive Metastatic Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-positive Metastatic Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine200 enrolled37 locationsNCT06551116
Recruiting
Phase 2

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer
Jules Bordet Institute87 enrolled1 locationNCT06595563
Recruiting
Phase 2

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

HER2-positive Metastatic Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
UNICANCER30 enrolled11 locationsNCT05800275
Recruiting
Not Applicable

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer

Stage IV Breast CancerHER2-positive Metastatic Breast Cancer
University of Miami20 enrolled1 locationNCT05959291
Recruiting
Phase 1

PRE-I-SPY Phase I/Ib Oncology Platform Program

Metastatic Breast CancerHER2-negative Breast CancerMetastatic Cancer+5 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226
Recruiting
Phase 1Phase 2

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Breast Cancer MetastaticAdvanced Breast CancerHER2-positive Metastatic Breast Cancer+1 more
Gustave Roussy, Cancer Campus, Grand Paris152 enrolled1 locationNCT06298084
Recruiting
Phase 3

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University312 enrolled1 locationNCT06278870